Diffuse Large B Cell Lymphoma Germinal Center B Cell Type C1333295
A fast-growing cancer of white blood cells that can occur at any age. Treatment typically involves chemotherapy and sometimes targeted therapy, with good response rates in many patients.
Key facts at a glance
- ICD-10
- C83.30, C83.36, C83.3A
- ICD-11
- 2A00.0
- Body system
- hematologic
- Severity
- severe
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(hematologic)Significant symptoms that substantially affect daily functioning.
Frequency: Varies
Painless lymph node enlargement
(hematologic)Unexplained weight loss
(general)Night sweats
(hematologic)Pruritus
(general)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Enhanced immunochemotherapy
The germinal center B-cell subtype typically has better prognosis with standard R-CHOP, but may benefit from intensifying rituximab dosing or adding lenalidomide to improve outcomes.
Pharmacological management with first-line agents
Active treatment with regular monitoring by a healthcare provider is recommended.
R-CHOP chemotherapy regimen
Standard first-line immunochemotherapy combining rituximab with cytotoxic agents represents the backbone of treatment for germinal center subtype diffuse large B-cell lymphoma.
Additional treatment options
Consolidation radiation therapy
Involves targeted radiation to sites of initial bulky disease (tumors >7.5-10cm) or residual PET-positive masses after chemotherapy completion to improve local control.
procedureAutologous stem cell transplant
High-dose chemotherapy with autologous stem cell rescue is considered for younger patients with high IPI scores or those with residual disease after standard therapy.
procedureMinimal residual disease monitoring
Advanced molecular testing including PET-CT imaging and liquid biopsy techniques to detect subclinical disease persistence and guide treatment decisions.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Diffuse Large B Cell Lymphoma Germinal Center B Cell Type C1333295?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Diffuse Large B Cell Lymphoma Germinal Center B Cell Type C1333295. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy